Fmoc-N-Me-Leu-OH

Fmoc-N-Me-Leu-OH is a specialized amino acid derivative widely recognized in peptide chemistry for its role as an N-methylated, Fmoc-protected form of leucine. This compound features an N-terminal fluorenylmethyloxycarbonyl (Fmoc) protecting group, which facilitates its incorporation into solid-phase peptide synthesis (SPPS) protocols. The N-methyl modification on the leucine residue imparts unique steric and conformational properties, making it particularly valuable for the design of peptides with enhanced structural rigidity, proteolytic stability, and bioactivity. Its use is central to the development of novel peptide-based molecules, including those with therapeutic, diagnostic, or biotechnological relevance, where precise control over peptide backbone conformation is critical.

Peptide Synthesis: Fmoc-N-Me-Leu-OH is primarily utilized in the stepwise assembly of peptides via Fmoc-based SPPS. The Fmoc group provides orthogonal protection, allowing for efficient elongation of peptide chains without unwanted side reactions. The N-methylation of the leucine residue serves to restrict backbone flexibility, which is often exploited to introduce conformational constraints in designed peptides. This property is particularly advantageous in the synthesis of cyclic peptides, peptidomimetics, and other structurally defined peptide analogs, where backbone rigidity can enhance target binding specificity and modulate biological activity.

Structure-Activity Relationship Studies: The incorporation of N-methylated amino acids, such as Fmoc-N-Me-Leu-OH, is instrumental in probing structure-activity relationships within peptide sequences. By selectively introducing N-methyl-leucine at strategic positions, researchers can systematically evaluate the impact of backbone methylation on receptor binding, conformational stability, and resistance to enzymatic degradation. Such studies enable the rational optimization of peptide leads for improved functional properties, informing the design of next-generation bioactive peptides and peptidomimetics.

Proteolytic Stability Enhancement: The N-methylation present in this derivative is a well-established strategy for increasing peptide resistance to proteolytic enzymes. When incorporated into peptide backbones, the methyl group on the amide nitrogen impedes recognition and cleavage by proteases, thereby prolonging peptide integrity in biological environments. This feature is crucial in the development of peptides intended for applications where stability against enzymatic degradation is required, such as in biochemical assays, molecular probes, or as research tools in complex biological systems.

Conformational Constraint Engineering: Researchers frequently employ Fmoc-N-Me-Leu-OH to introduce conformational constraints into synthetic peptides. The N-methyl group restricts rotation around the peptide bond, favoring specific secondary structures such as β-turns or helical motifs. This capability is leveraged in the rational design of peptides with defined three-dimensional shapes, which can be critical for mimicking protein-protein interaction interfaces, generating stable scaffolds for molecular recognition, or engineering peptides with improved pharmacological profiles.

Peptide Library Construction: In combinatorial chemistry and high-throughput screening, the use of N-methylated amino acids like Fmoc-N-Me-Leu-OH expands the diversity and functional space of synthetic peptide libraries. By incorporating this derivative into library designs, researchers can access peptide variants with altered backbone properties, enhanced metabolic stability, and novel conformational features. This approach is valuable for the identification of novel ligands, inhibitors, or molecular probes with tailored physicochemical and biological characteristics, supporting advanced discovery efforts in chemical biology and drug development.

1. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

2. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

3. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet

4. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

5. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction